Year None20222021202020192018 Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival Sep 21, 2022 Read More Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody Aug 31, 2022 Read More Sensei Biotherapeutics to Participate in Upcoming Investor Conferences Aug 23, 2022 Read More Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights Aug 09, 2022 Read More Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer Jun 01, 2022 Read More Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference May 25, 2022 Read More Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights May 10, 2022 Read More Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights Mar 10, 2022 Read More Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors Mar 09, 2022 Read More Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference Mar 03, 2022 Read More Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12
